Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
Dengue virus (DENV) encodes a unique protease (NS3/NS2B) essential for its maturation and infectivity and, it has become a key target for anti-viral drug design to treat dengue and other flavivirus related infections. Present investigation established that some of the drug molecules currently used m...
Guardado en:
Autores principales: | R V Sriram Uday, Rajdip Misra, Annaram Harika, Sandip Dolui, Achintya Saha, Uttam Pal, V Ravichandiran, Nakul C Maiti |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5cdadd6cff564a66ac6bfef33c321c75 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Sandip Ganguly, et al.
Publicado: (2021) -
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat YF, et al.
Publicado: (2016) -
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
por: Reck M, et al.
Publicado: (2015) -
Structure of the NS2B-NS3 protease from Zika virus after self-cleavage
por: Wint Wint Phoo, et al.
Publicado: (2016) -
Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda M, et al.
Publicado: (2015)